Acute pericarditis and pleural effusion complicating cytarabine chemotherapy

Onkologie. 2003 Aug;26(4):348-50. doi: 10.1159/000072094.

Abstract

Background: Pericarditis is a rare but possibly severe complication of treatment of acute leukemia with cytarabine.

Case report: We report a possibly cytarabine-induced acute pericarditis and pleuritis with a rapid onset. A patient with acute myelomonocytic leukemia developed an isolated pericarditis 3 weeks after the first course of chemotherapy with cytarabine and idarubicin. The second course of chemotherapy with cytarabine and amsacrine was started after clinical improvement; 3 days later an acute pericarditis with a large pericardial effusion accompanied by a left pleural effusion developed. A pericardio- and pleuracentesis was performed and the symptoms improved rapidly without reaccumulation of the fluid. The third course of chemotherapy with mitoxantrone and etoposide was completed without further cardiopulmonary complications.

Conclusion: The differential diagnosis of pericarditis in the setting of chemotherapy with cytarabine should include cytarabine- induced pericarditis. The pathogenesis remains unclear, directly toxic and immunological mechanisms are suggested. Severe progression with massive pericardial effusion necessitating risky pericardiocentesis can occur and therefore a therapy with high-dose corticosteroids should be considered early.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Antimetabolites, Antineoplastic / adverse effects*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cytarabine / adverse effects*
  • Cytarabine / therapeutic use
  • Humans
  • Leukemia, Myelomonocytic, Acute / drug therapy*
  • Male
  • Middle Aged
  • Pericarditis / chemically induced*
  • Pericarditis / diagnosis
  • Pleural Effusion / chemically induced*
  • Pleural Effusion / diagnosis
  • Recurrence

Substances

  • Antimetabolites, Antineoplastic
  • Cytarabine